{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:13:15Z","timestamp":1789647195411,"version":"4.0.0"},"reference-count":145,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003246","name":"NWO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001722","name":"Koninklijke Nederlandse Akademie van Wetenschappen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001722","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["10104161"],"award-info":[{"award-number":["10104161"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ymgme.2025.109698","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:39:14Z","timestamp":1764808754000},"page":"109698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Navigating molecular therapies: The emerging role of mRNA in treating inherited metabolic diseases"],"prefix":"10.1016","volume":"147","author":[{"given":"J.A.","family":"Castro-Alp\u00edzar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Lenderink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.E.S.","family":"Nieuwenhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.A.","family":"Kooijmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ymgme.2025.109698_bb0255","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/jimd.12348","article-title":"An international classification of inherited metabolic disorders (ICIMD)","volume":"44","author":"Ferreira","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109698_bb0065","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jpeds.2022.08.053","article-title":"Extended risk of mortality in children with inborn errors of metabolism: a longitudinal cohort study","volume":"252","author":"Auger","year":"2023","journal-title":"J. Pediatr."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109698_bb0440","first-page":"6","article-title":"Diagnosis and early management of inborn errors of metabolism presenting around the time of birth","volume":"95","author":"Leonard","year":"2006","journal-title":"Acta Paediatr."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109698_bb0125","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1177\/0884533615586201","article-title":"Inherited metabolic disorders: aspects of chronic nutrition management","volume":"30","author":"Boyer","year":"2015","journal-title":"Nutr. Clin. Pract."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109698_bb0240","doi-asserted-by":"crossref","DOI":"10.1111\/petr.14625","article-title":"Current status and future directions of liver transplantation for metabolic liver disease in children","volume":"28","author":"Eldredge","year":"2024","journal-title":"Pediatr. Transplant."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109698_bb0455","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/lt.25433","article-title":"Evolving trends in liver transplant for metabolic liver disease in the United States","volume":"25","author":"McKiernan","year":"2019","journal-title":"Liver Transpl."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109698_bb0530","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.70100","article-title":"The evolving trend of liver transplantation in metabolic diseases: from origins to current perspectives","volume":"48","author":"Pietrobattista","year":"2025","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109698_bb0680","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/asheducation-2011.1.285","article-title":"Stem cell transplantation in inherited metabolic disorders","volume":"2011","author":"Wynn","year":"2011","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109698_bb0685","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s12185-022-03383-z","article-title":"Allogeneic hematopoietic stem cell transplantation for inherited metabolic disorders","volume":"116","author":"Yabe","year":"2022","journal-title":"Int. J. Hematol."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109698_bb0485","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/MOT.0b013e3283399dbd","article-title":"Liver transplantation for inherited metabolic disorders of the liver","volume":"15","author":"Moini","year":"2010","journal-title":"Curr. Opin. Organ Transplant."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109698_bb0510","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/petr.12741","article-title":"Liver transplantation for pediatric inherited metabolic disorders: considerations for indications, complications, and perioperative management","volume":"20","author":"Oishi","year":"2016","journal-title":"Pediatr. Transplant."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109698_bb0550","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"21","key":"10.1016\/j.ymgme.2025.109698_bb0600","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2023114760","article-title":"RNA-based medicine: from molecular mechanisms to therapy","volume":"42","author":"Sparmann","year":"2023","journal-title":"EMBO J."},{"issue":"7785","key":"10.1016\/j.ymgme.2025.109698_bb0030","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2025.109698_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115026","article-title":"Gene editing therapeutics based on mRNA delivery","volume":"200","author":"Popovitz","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.ymgme.2025.109698_bb0560","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","article-title":"Base editing: precision chemistry on the genome and transcriptome of living cells","volume":"19","author":"Rees","year":"2018","journal-title":"Nat. Rev. Genet."},{"issue":"4949","key":"10.1016\/j.ymgme.2025.109698_bb0670","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.ymgme.2025.109698_bb0110","article-title":"Intracellular protein topogenesis (protein translocation across membranes\/protein integration into membranes\/posttranslocational sorting\/topogenic sequences\/phylogeny of membranes and compartments)","volume":"77","author":"Blobel","year":"1980","journal-title":"Cell Biol."},{"key":"10.1016\/j.ymgme.2025.109698_bb0300","series-title":"Nature Reviews Materials","article-title":"Tools for translation: non-viral materials for therapeutic mRNA delivery","volume":"Vol. 2","author":"Hajj","year":"2017"},{"issue":"4","key":"10.1016\/j.ymgme.2025.109698_bb0515","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.ymgme.2025.109698_bb0580","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics \u2014 developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.ymgme.2025.109698_bb0385","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of Pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2025.109698_bb0715","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.gene.2019.05.008","article-title":"Improved translation efficiency of therapeutic mRNA","volume":"707","author":"Zarghampoor","year":"2019","journal-title":"Gene"},{"issue":"2","key":"10.1016\/j.ymgme.2025.109698_bb0310","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.39","article-title":"Cap 1 messenger RNA synthesis with Co-transcriptional CleanCap \u00ae Analog by in vitro transcription","volume":"1","author":"Henderson","year":"2021","journal-title":"Curr. Protoc."},{"key":"10.1016\/j.ymgme.2025.109698_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15476286.2018.1450054","article-title":"Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA","author":"Asrani","year":"2018","journal-title":"RNA Biol."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109698_bb0610","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s12015-018-9805-1","article-title":"Optimization of synthetic mRNA for highly efficient translation and its application in the generation of endothelial and hematopoietic cells from human and primate pluripotent stem cells","volume":"14","author":"Suknuntha","year":"2018","journal-title":"Stem Cell Rev. Rep."},{"issue":"21","key":"10.1016\/j.ymgme.2025.109698_bb0015","doi-asserted-by":"crossref","first-page":"9329","DOI":"10.1093\/nar\/gkr586","article-title":"Nucleoside modifications in RNA limit activation of 2\u2032-5\u2032-oligoadenylate synthetase and increase resistance to cleavage by RNase L","volume":"39","author":"Anderson","year":"2011","journal-title":"Nucleic Acids Res."},{"issue":"17","key":"10.1016\/j.ymgme.2025.109698_bb0020","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1093\/nar\/gkq347","article-title":"Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation","volume":"38","author":"Anderson","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymgme.2025.109698_bb0025","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jconrel.2015.08.051","article-title":"N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice","volume":"217","author":"Andries","year":"2015","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.ymgme.2025.109698_bb0380","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.ymgme.2025.109698_bb0095","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.3390\/pharmaceutics13122090","article-title":"mRNA, a revolution in biomedicine","volume":"13","author":"Baptista","year":"2021","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.ymgme.2025.109698_bb0235","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0092-8674(02)01137-6","article-title":"The poly(A) tail of mRNAs","volume":"111","author":"Dreyfus","year":"2002","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.ymgme.2025.109698_bb0315","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","article-title":"Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells","volume":"108","author":"Holtkamp","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ymgme.2025.109698_bb0330","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"issue":"9","key":"10.1016\/j.ymgme.2025.109698_bb0525","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1021\/acs.nanolett.7b02664","article-title":"Boosting intracellular delivery of lipid nanoparticle-encapsulated mRNA","volume":"17","author":"Patel","year":"2017","journal-title":"Nano Lett."},{"key":"10.1016\/j.ymgme.2025.109698_bb0120","series-title":"Advanced Drug Delivery Reviews","first-page":"79","article-title":"Lipid-based nanoparticle technologies for liver targeting","volume":"vols. 154\u2013155","author":"B\u00f6ttger","year":"2020"},{"issue":"5","key":"10.1016\/j.ymgme.2025.109698_bb0295","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.70078","article-title":"Delivering the message: translating mRNA therapy for liver inherited metabolic diseases","volume":"48","author":"Gurung","year":"2025","journal-title":"J. Inherit. Metab. Dis."},{"issue":"8009","key":"10.1016\/j.ymgme.2025.109698_bb0410","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/s41586-024-07266-7","article-title":"Interim analyses of a first-in-human phase 1\/2 mRNA trial for propionic acidaemia","volume":"628","author":"Koeberl","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2025.109698_bb0480","author":"Moderna, Inc"},{"key":"10.1016\/j.ymgme.2025.109698_bb0460","first-page":"1","article-title":"Safety and tolerability of ARCT-810 mRNA in early trials for ornithine transcarbamylase deficiency","volume":"47","author":"McNutt","year":"2024","journal-title":"Abstr. J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109698_bb0050","author":"Arcturus Therapeutics"},{"key":"10.1016\/j.ymgme.2025.109698_bb0475","series-title":"Glycogen Storage Disease Type 1a (GSD1a) (mRNA-3745) [Presentation]","author":"Moderna, Inc","year":"2023"},{"key":"10.1016\/j.ymgme.2025.109698_bb0620","author":"Ultragenyx Pharmaceutical Inc"},{"key":"10.1016\/j.ymgme.2025.109698_bb0010","author":"Aima"},{"key":"10.1016\/j.ymgme.2025.109698_bb0105","series-title":"Orphanet Journal of Rare Diseases (Vol. 9, Issue 1)","article-title":"Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia","author":"Baumgartner","year":"2014"},{"issue":"4","key":"10.1016\/j.ymgme.2025.109698_bb0675","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ymgme.2017.10.002","article-title":"Propionyl-CoA carboxylase \u2013 a review","volume":"122","author":"Wongkittichote","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109698_bb0345","article-title":"Chemical modifications of adenine base editor mRNA and guide RNA expand its application scope","volume":"11","author":"Jiang","year":"2020","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109698_bb0265","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/MOP.0000000000000422","article-title":"Methylmalonic and propionic acidemias: clinical management update","volume":"28","author":"Fraser","year":"2016","journal-title":"Curr. Opin. Pediatr."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109698_bb0415","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s10545-015-9840-x","article-title":"The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype","volume":"38","author":"K\u00f6lker","year":"2015","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109698_bb0075","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1038\/s41467-024-47460-9","article-title":"Characterizing the mechanism of action for mRNA therapeutics for the treatment of propionic acidemia, methylmalonic acidemia, and phenylketonuria","volume":"15","author":"Baek","year":"2024","journal-title":"Nat. Commun."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2025.109698_bb0205","article-title":"Improved therapeutic efficacy in two mouse models of methylmalonic acidemia (MMA) using a second-generation mRNA therapy","volume":"143","author":"Coughlan","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109698_bb0450","article-title":"The utility of methylmalonic acid, methylcitrate acid, and homocysteine in dried blood spots for therapeutic monitoring of three inherited metabolic diseases","volume":"11","author":"Liu","year":"2024","journal-title":"Front. Nutr."},{"issue":"8","key":"10.1016\/j.ymgme.2025.109698_bb0335","doi-asserted-by":"crossref","DOI":"10.3390\/children10081368","article-title":"Diagnostic and management issues in patients with late-onset ornithine Transcarbamylase deficiency","volume":"10","author":"Ibrahim","year":"2023","journal-title":"Children"},{"issue":"10","key":"10.1016\/j.ymgme.2025.109698_bb0360","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2765","article-title":"Liver transplantation in rare late-onset ornithine transcarbamylase deficiency with central nervous system injury: a case report and review of the literature","volume":"12","author":"Jin","year":"2022","journal-title":"Brain Behav."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109698_bb0710","article-title":"Restoring ornithine transcarbamylase (OTC) activity in an OTC-deficient mouse model using LUNAR-OTC mRNA","volume":"2","author":"Yu","year":"2022","journal-title":"Clin. Transl. Discov."},{"issue":"12","key":"10.1016\/j.ymgme.2025.109698_bb0190","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nrendo.2010.189","article-title":"Glycogen storage disease type I and G6Pase-\u03b2 deficiency: etiology and therapy","volume":"6","author":"Chou","year":"2010","journal-title":"Nat. Rev. Endocrinol."},{"issue":"11","key":"10.1016\/j.ymgme.2025.109698_bb0405","doi-asserted-by":"crossref","DOI":"10.1038\/gim.2014.128","article-title":"Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics","volume":"16","author":"Kishnani","year":"2014","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109698_bb0155","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1038\/s41467-021-23318-2","article-title":"mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease","volume":"12","author":"Cao","year":"2021","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109698_bb0590","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2174\/1566524024605752","article-title":"Molecular characterization of glycogen storage disease type III","volume":"2","author":"Shen","year":"2002","journal-title":"Curr. Mol. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109698_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107583","article-title":"Phenylketonuria and the brain","volume":"139","author":"Rovelli","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109698_bb0365","author":"Jinek"},{"issue":"15","key":"10.1016\/j.ymgme.2025.109698_bb0555","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","article-title":"Therapeutic in vivo delivery of gene editing agents","volume":"185","author":"Raguram","year":"2022","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ymgme.2025.109698_bb0470","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrg2988","article-title":"Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges","volume":"12","author":"Mingozzi","year":"2011","journal-title":"Nat. Rev. Genet."},{"issue":"5","key":"10.1016\/j.ymgme.2025.109698_bb0655","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymgme.2025.109698_bb0585","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev.biochem.77.061306.125255","article-title":"Mechanism of eukaryotic homologous recombination","volume":"77","author":"San Filippo","year":"2008","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ymgme.2025.109698_bb0420","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ymgme.2025.109698_bb0160","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.molcel.2012.07.029","article-title":"Playing the end game: DNA double-Strand break repair pathway choice","volume":"47","author":"Chapman","year":"2012","journal-title":"Mol. Cell"},{"issue":"7681","key":"10.1016\/j.ymgme.2025.109698_bb0270","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of T to G C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ymgme.2025.109698_bb0325","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/ehjcvp\/pvad103","article-title":"VERVE-101: a promising CRISPR-based gene editing therapy that reduces LDL-C and PCSK9 levels in HeFH patients","volume":"10","author":"Horie","year":"2024","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"8","key":"10.1016\/j.ymgme.2025.109698_bb0320","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/13543784.2024.2369747","article-title":"VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol","volume":"33","author":"Hooper","year":"2024","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ymgme.2025.109698_bb0635","author":"Verve Therapeutics"},{"key":"10.1016\/j.ymgme.2025.109698_bb0650","article-title":"Base editing gene therapy for heterozygous familial hypercholesterolemia [preprint]","author":"Wan","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.ymgme.2025.109698_bb0700","series-title":"First Patient Dosed in Clinical Trial of YOLT-101 for the Treatment of Familial Hypercholesterolemia [Press Release]","author":"YolTech Therapeutics","year":"2024"},{"key":"10.1016\/j.ymgme.2025.109698_bb0695","series-title":"YolTech Announces First Clinical Data from Ongoing Investigator-initiated Trial of YOLT-101, an In-vivo Base Editing Therapy for Familial Hypercholesterolemia [Press Release]","author":"YolTech Therapeutics Co., Ltd","year":"2025"},{"key":"10.1016\/j.ymgme.2025.109698_bb0215","series-title":"Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress","article-title":"BEAM-302: A potential base editing therapeutic for alpha-1 antitrypsin deficiency (Alpha-1)[conference abstract]","author":"Currier","year":"2025"},{"key":"10.1016\/j.ymgme.2025.109698_bb0705","series-title":"YolTech Therapeutics Announces Positive Clinical Data for YOLT-203, an In Vivo Gene-Editing Therapy for Primary Hyperoxaluria Type 1 (PH1) [Press Release]","author":"YolTech Therapeutics","year":"2025"},{"key":"10.1016\/j.ymgme.2025.109698_bb0040","series-title":"Arbor Biotechnologies Announces First Patient Dosed at Mayo Clinic in the redePHine Phase 1\/2 Study of ABO-101, an Investigational Gene Editing Treatment for Primary Hyperoxaluria Type 1","author":"Arbor Biotechnologies, Inc","year":"2025"},{"issue":"22","key":"10.1016\/j.ymgme.2025.109698_bb0500","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMoa2504747","article-title":"Patient-specific in vivo gene editing to treat a rare genetic disease","volume":"392","author":"Musunuru","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2025.109698_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100062","article-title":"Lipoprotein metabolism in familial hypercholesterolemia","volume":"62","author":"Chemello","year":"2021","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109698_bb0430","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","article-title":"Efficacy and safety of an investigational single-course CRISPR BASE-editing therapy targeting PCSK9 in nonhuman primate and mouse models","volume":"147","author":"Lee","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2025.109698_bb0630","author":"Verve Therapeutics"},{"key":"10.1016\/j.ymgme.2025.109698_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.118496","article-title":"An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves precise and durable liver editing in nonclinical studies [abstract]","volume":"395","author":"Lee","year":"2024","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.ymgme.2025.109698_bb0250","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1183\/20734735.015018","article-title":"Update on \u03b11-antitrypsin deficiency","volume":"14","author":"Ferrarotti","year":"2018","journal-title":"Breathe"},{"key":"10.1016\/j.ymgme.2025.109698_bb0085","series-title":"BEAM-302 Decreases Hepatic Aggregates of Mutant AAT and Increases Circulating Functional AAT in Rodent Models of Alpha-1 Antitrypsin Deficiency [Poster Presentation]","author":"Banerjee","year":"2023"},{"issue":"3","key":"10.1016\/j.ymgme.2025.109698_bb0285","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41581-022-00661-1","article-title":"Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope","volume":"19","author":"Groothoff","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109698_bb0355","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymthe.2024.10.003","article-title":"Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption","volume":"33","author":"Jiang","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2025.109698_bb0045","series-title":"Arbor Biotechnologies to Present Preclinical Data for ABO-101 in PH1 at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting","author":"Arbor Biotechnologies, Inc","year":"2025"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109698_bb0535","first-page":"56","article-title":"Classifying molecular phenotypes of G6PC variants for pathogenic properties and to guide therapeutic development","volume":"60","author":"Plona","year":"2021","journal-title":"JIMD Rep."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109698_bb0055","doi-asserted-by":"crossref","first-page":"9729","DOI":"10.1038\/s41467-024-54108-1","article-title":"Base-editing corrects metabolic abnormalities in a humanized mouse model for glycogen storage disease type-Ia","volume":"15","author":"Arnaoutova","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymgme.2025.109698_bb0185","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cca.2021.11.029","article-title":"Unfavorable clinical outcomes in patients with carbamoyl phosphate synthetase 1 deficiency","volume":"526","author":"Choi","year":"2022","journal-title":"Clin. Chim. Acta"},{"issue":"636","key":"10.1016\/j.ymgme.2025.109698_bb0115","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl9238","article-title":"In vivo prime editing of a metabolic liver disease in mice","volume":"14","author":"B\u00f6ck","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymgme.2025.109698_bb0570","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-025-01399-4","article-title":"Treatment of a metabolic liver disease in mice with a transient prime editing approach","author":"Rothgangl","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymgme.2025.109698_bb0625","series-title":"Immunogenicity Assessment for Therapeutic Protein Products: Guidance for Industry","author":"U.S. Food and Drug Administration","year":"2014"},{"issue":"3","key":"10.1016\/j.ymgme.2025.109698_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102636","article-title":"Off-target effects in CRISPR-Cas genome editing for human therapeutics: progress and challenges","volume":"36","author":"Kalter","year":"2025","journal-title":"Mol. Ther. Nucleic Acids."},{"key":"10.1016\/j.ymgme.2025.109698_bb0665","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2022.1050507","article-title":"CRISPR nuclease off-target activity and mitigation strategies","volume":"4","author":"Wienert","year":"2022","journal-title":"Front. Genome Ed."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109698_bb0175","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41576-022-00541-1","article-title":"Prime editing for precise and highly versatile genome manipulation","volume":"24","author":"Chen","year":"2023","journal-title":"Nat. Rev. Genet."},{"issue":"12","key":"10.1016\/j.ymgme.2025.109698_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103479","article-title":"The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory","volume":"24","author":"Ndeupen","year":"2021","journal-title":"IScience"},{"key":"10.1016\/j.ymgme.2025.109698_bb0520","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jconrel.2021.12.027","article-title":"Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE)","volume":"344","author":"Parhiz","year":"2022","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.ymgme.2025.109698_bb0425","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1089\/nat.2018.0740","article-title":"Systemic alanine glyoxylate aminotransferase mRNA improves glyoxylate metabolism in a mouse model of primary hyperoxaluria type 1","volume":"29","author":"Kukreja","year":"2019","journal-title":"Nucleic Acid Ther."},{"issue":"5","key":"10.1016\/j.ymgme.2025.109698_bb0640","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3390\/biomedicines9050530","article-title":"Non-immunotherapy application of lnp-mrna: maximizing efficacy and safety","volume":"9","author":"Vlatkovic","year":"2021","journal-title":"Biomedicines"},{"issue":"15","key":"10.1016\/j.ymgme.2025.109698_bb0690","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adt9694","article-title":"Preclinical evaluation of AGT mRNA replacement therapy for primary hyperoxaluria type I disease","volume":"11","author":"Yang","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymgme.2025.109698_bb0245","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jconrel.2021.11.042","article-title":"Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement","volume":"341","author":"Estap\u00e9-Senti","year":"2022","journal-title":"J. Control. Release"},{"issue":"7993","key":"10.1016\/j.ymgme.2025.109698_bb0490","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41586-023-06800-3","article-title":"N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting","volume":"625","author":"Mulroney","year":"2024","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ymgme.2025.109698_bb0165","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109698_bb0195","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/jimd.12637","article-title":"Liver directed adeno-associated viral vectors to treat metabolic disease","volume":"47","author":"Chuecos","year":"2024","journal-title":"J. Inherit. Metab. Dis."},{"issue":"10","key":"10.1016\/j.ymgme.2025.109698_bb0220","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.ymthe.2021.08.031","article-title":"AAV integration in human hepatocytes","volume":"29","author":"Dalwadi","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2025.109698_bb0395","article-title":"Dual SORT LNPs for multi-organ base editing","author":"Kim","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymgme.2025.109698_bb0100","article-title":"P008: A first-in-human, single-arm, open-label phase 1\/2 study evaluating ECUR-506 in neonatal OTC deficiency: initial observations","volume":"1","author":"Baruteau","year":"2025","journal-title":"GIM Open"},{"issue":"17","key":"10.1016\/j.ymgme.2025.109698_bb0230","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/sj.gt.3301541","article-title":"Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors","volume":"8","author":"Donsante","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymgme.2025.109698_bb0260","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.omtm.2018.02.003","article-title":"Influence of pre-existing anti-capsid neutralizing and binding antibodies on AAV vector transduction","volume":"9","author":"Fitzpatrick","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109698_bb0305","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1038\/s41467-019-12449-2","article-title":"High levels of AAV vector integration into CRISPR-induced DNA breaks","volume":"10","author":"Hanlon","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109698_bb0465","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/v13010101","article-title":"Completion of the AAV structural atlas: serotype capsid structures reveals clade-specific features","volume":"13","author":"Mietzsch","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ymgme.2025.109698_bb0545","author":"Prime Medicine, Inc"},{"key":"10.1016\/j.ymgme.2025.109698_bb0210","author":"CRISPR Therapeutics"},{"issue":"12","key":"10.1016\/j.ymgme.2025.109698_bb0340","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41591-018-0199-z","article-title":"Systemic messenger RNA as an etiological treatment for acute intermittent porphyria","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109698_bb0200","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/gutjnl-2024-332619","article-title":"Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates","volume":"74","author":"C\u00f3rdoba","year":"2025","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109698_bb0375","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-64017-0","article-title":"Systemic modified messenger RNA for replacement therapy in alpha 1-antitrypsin deficiency","volume":"10","author":"Karadagi","year":"2020","journal-title":"Sci. Rep."},{"issue":"42","key":"10.1016\/j.ymgme.2025.109698_bb0615","doi-asserted-by":"crossref","first-page":"21150","DOI":"10.1073\/pnas.1906182116","article-title":"Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency","volume":"116","author":"Truong","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2025.109698_bb0390","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.omtn.2022.04.012","article-title":"Intermittent lipid nanoparticle mRNA administration prevents cortical dysmyelination associated with arginase deficiency","volume":"28","author":"Khoja","year":"2022","journal-title":"Mol. Ther. Nucleic Acids."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109698_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11061735","article-title":"ASL mRNA-LNP therapeutic for the treatment of Argininosuccinic aciduria enables survival benefit in a mouse model","volume":"11","author":"Daly","year":"2023","journal-title":"Biomedicines"},{"issue":"729","key":"10.1016\/j.ymgme.2025.109698_bb0290","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adh1334","article-title":"mRNA therapy corrects defective glutathione metabolism and restores ureagenesis in preclinical argininosuccinic aciduria","volume":"16","author":"Gurung","year":"2024","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109698_bb0080","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ymthe.2019.09.018","article-title":"Novel mRNA-based therapy reduces toxic galactose metabolites and overcomes galactose sensitivity in a mouse model of classic galactosemia","volume":"28","author":"Balakrishnan","year":"2020","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109698_bb0035","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/psp4.12301","article-title":"Quantitative systems pharmacology model of hUGT1A1-modRNA encoding for the UGT1A1 enzyme to treat Crigler-Najjar syndrome type 1","volume":"7","author":"Apgar","year":"2018","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ymgme.2025.109698_bb0275","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.omtm.2023.02.007","article-title":"Lipid nanoparticle-encapsulated mRNA therapy corrects serum total bilirubin level in Crigler-Najjar syndrome mouse model","volume":"29","author":"Greig","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109698_bb0730","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ajhg.2019.02.003","article-title":"Systemic mRNA therapy for the treatment of Fabry disease: preclinical studies in wild-type mice, Fabry mouse model, and wild-type non-human Primates","volume":"104","author":"Zhu","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2025.109698_bb0145","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.omtm.2022.07.006","article-title":"mRNA-based therapy proves superior to the standard of care for treating hereditary tyrosinemia 1 in a mouse model","volume":"26","author":"Cacicedo","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"52","key":"10.1016\/j.ymgme.2025.109698_bb0180","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201805308","article-title":"Dendrimer-based lipid nanoparticles deliver therapeutic FAH mRNA to normalize liver function and extend survival in a mouse model of hepatorenal tyrosinemia type I","volume":"30","author":"Cheng","year":"2018","journal-title":"Adv. Mater."},{"issue":"17\u201318","key":"10.1016\/j.ymgme.2025.109698_bb0280","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1089\/hum.2024.047","article-title":"Lipid nanoparticle mRNA therapy improves survival and reduces serum branched-chain amino acids in mouse models of maple syrup urine disease","volume":"35","author":"Greig","year":"2024","journal-title":"Hum. Gene Ther."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109698_bb0660","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.jhep.2020.12.010","article-title":"Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB\/c.Abcb4\u2212\/\u2212 mouse model of PFIC3","volume":"74","author":"Wei","year":"2021","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.ymgme.2025.109698_bb0150","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.ymthe.2019.04.017","article-title":"mRNA therapy improves metabolic and Behavioral abnormalities in a murine model of citrin deficiency","volume":"27","author":"Cao","year":"2019","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109698_bb0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2022.106982","article-title":"Synthetic mRNA rescues very long-chain acyl-CoA dehydrogenase deficiency in patient fibroblasts and a murine model","volume":"138","author":"Zhao","year":"2023","journal-title":"Mol. Genet. Metab."},{"issue":"14","key":"10.1016\/j.ymgme.2025.109698_bb0725","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1093\/hmg\/ddad076","article-title":"Messenger RNA rescues medium-chain acyl-CoA dehydrogenase deficiency in fibroblasts from patients and a murine model","volume":"32","author":"Zhao","year":"2023","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109698_bb0140","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-39246-2","article-title":"Rapid and definitive treatment of phenylketonuria in variant-humanized mice with corrective editing","volume":"14","author":"Brooks","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109698_bb0595","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41551-019-0357-8","article-title":"Adenine base editing in an adult mouse model of tyrosinaemia","volume":"4","author":"Song","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymgme.2025.109698_bb0350","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1038\/s41467-020-19156-3","article-title":"Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia","volume":"11","author":"Jiang","year":"2020","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.ymgme.2025.109698_bb0565","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41587-021-00933-4","article-title":"In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels","volume":"39","author":"Rothgangl","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymgme.2025.109698_bb0135","series-title":"Molecular Therapy Methods and Clinical Development","article-title":"Rational design of lipid nanoparticles for enabling gene therapies","volume":"vol. 33, Issue 3","author":"Brimacombe","year":"2025"},{"key":"10.1016\/j.ymgme.2025.109698_bb0400","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-024-02523-6","article-title":"AAV capsid prioritization in normal and steatotic human livers maintained by machine perfusion","author":"Kim","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymgme.2025.109698_bb0605","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-50093-7","article-title":"Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation","volume":"15","author":"Su","year":"2024","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.ymgme.2025.109698_bb0445","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/s41565-024-01680-8","article-title":"Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells","volume":"19","author":"Lian","year":"2024","journal-title":"Nat. Nanotechnol."},{"issue":"6656","key":"10.1016\/j.ymgme.2025.109698_bb0130","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.ade6967","article-title":"In vivo hematopoietic stem cell modification by mRNA delivery","volume":"381","author":"Breda","year":"2023","journal-title":"Science (New York, N.Y.)"},{"issue":"2","key":"10.1016\/j.ymgme.2025.109698_bb0090","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","article-title":"Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins","volume":"185","author":"Banskota","year":"2022","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.ymgme.2025.109698_bb0070","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1177\/0883073813495959","article-title":"Clinical trials in rare disease: challenges and opportunities","volume":"28","author":"Augustine","year":"2013","journal-title":"J. Child Neurol."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109698_bb0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107612","article-title":"Challenges and strategies for clinical trials in propionic and methylmalonic acidemias","volume":"139","author":"Vockley","year":"2023","journal-title":"Mol. Genet. Metab."},{"issue":"25","key":"10.1016\/j.ymgme.2025.109698_bb0005","article-title":"How to create personalized gene editing platforms: next steps toward interventional genetics","volume":"S0002-9297","author":"Ahrens-Nicklas","year":"2025","journal-title":"Am. J. Hum. Genet."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719225006900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719225006900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:10:35Z","timestamp":1777608635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719225006900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":145,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1096719225006900"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2025.109698","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Navigating molecular therapies: The emerging role of mRNA in treating inherited metabolic diseases","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2025.109698","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109698"}}